|
|
|
|
|
|
IMBRUVICA
and Its Impact on Patients
|
|
This
month’s Innovation That Matters
featuresHeow Tan, Chief of
Quality and Technical Operations at
Pharmacyclics. Tan joined
Pharmacyclics in 2012 leading Global Quality,
CMC Development, Global Manufacturing, Supply
Chain, and Pharmacyclics International
Operations. Pharmacyclics lead product,
Ibrutinib, with the trade name IMBRUVICA®, is
one of the early molecules to receive US FDA
Breakthrough Therapy Designation for
Oncology. It is also the only drug that
received 3 Breakthrough Therapy Designations
from the US FDA.
continue
reading... |
| |
|
